Zhimin Gao

4 weeks ago | onlinelibrary.wiley.com | Zhimin Gao |Lei Zhang |Zhen Li |Xu Qin

1 Introduction There is an increasing variety of treatment options regarding locally advanced or metastatic urothelial carcinoma (UC), such as immune checkpoint inhibitors (ICIs) [1], antibody–drug conjugates (ADCs) [2], and fibroblast growth factor receptor (FGFR) inhibitors [3]. Nevertheless, the standard initial therapeutic approach for advanced bladder cancer (BC) still involves combination chemotherapy based on cisplatin [4].